Improving implant stability by strengthening the bone

AddBIO AB has developed Zolidd®, a proprietary bioactive nanolayer for orthopedic and dental implants that releases bisphosphonate, a bone strengthening drug. A randomized clinical trial by professor Aspenberg & co-workers, published in Bone in February 2012, shows that dental implants with a bisphosphonate nanolayer have improved stability.

Millions of people worldwide have dental implants, i.e. screws inserted to support artificial teeth. The first period after surgery, the implant is often not stable enough to enable chewing. It may take several months for the bone around the implant to heal and become strong enough for the patient to regain normal chewing function.
“The study shows that local bisphosphonate improves implant stability, meaning that the time until normal chewing function could be shortened, thus reducing the suffering for the patient”, says Professor Per Aspenberg, Linköping University Hospital, co-founder of AddBIO.

Zolidd is the first application from a platform technology designed for local release of drugs from medical implants, developed by Professors Per Aspenberg and Penti Tengvall, Linköping University.  Zolidd can be added to a variety of device materials, strengthening the bone without changing the underlying properties of the device itself.

Screw loosening is a major problem in trauma and CMF surgery, particularly in weak bone. Adding Zolidd to a device improves the holding power and holds great promise in reducing loosening, cut-out, and failure in a number of clinical applications.
More clinical studies are underway.

Please contact us to learn more about how Zolidd can improve the holding power of your devices.